| Galvin, James |
LUCINDA, NCT03649724: The Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's |
|
|
| Recruiting | 2 | 180 | US | Placebo, Eligard 22.5Mg Suspension for Injection | Weill Medical College of Cornell University, National Institute on Aging (NIA), Tolmar Pharmaceuticals | Alzheimer Disease, Mild Cognitive Impairment | 12/25 | 02/26 | | |
NCT06224205: Digital Detection of Dementia (D Cubed) Studies: D3 |
|
|
| Recruiting | N/A | 3150 | US | Passive Digital Marker for screening for ADRD, Patient reported outcome (QDRS) for screening for ADRD | Indiana University, National Institute on Aging (NIA) | Alzheimer Disease and Related Dementias (ADRD) | 11/25 | 11/25 | | |
| Active, not recruiting | N/A | 300 | US | | University of Florida, National Institute on Aging (NIA) | Dementia With Lewy Bodies | 02/25 | 05/25 | | |
| Completed | N/A | 6533 | US | Passive Digital Marker for screening for ADRD, Patient reported outcome (QDRS) for screening for ADRD | Indiana University, National Institute on Aging (NIA) | Alzheimer Disease and Related Dementias (ADRD) | 07/24 | 07/24 | | |
| Henriquez, Adolfo M |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies |
|
|
| Completed | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia with Lewy Bodies | 11/24 | 11/24 | | |
LUCINDA, NCT03649724: The Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's |
|
|
| Recruiting | 2 | 180 | US | Placebo, Eligard 22.5Mg Suspension for Injection | Weill Medical College of Cornell University, National Institute on Aging (NIA), Tolmar Pharmaceuticals | Alzheimer Disease, Mild Cognitive Impairment | 12/25 | 02/26 | | |
